Verve gets New Zealand clearance to test base editing therapy directly in the human body
Two years ago, Intellia and Editas Medicine ventured into the field of science fiction when the biotechs directly edited genes in humans.
Now, following behind those two companies, which have reported limited data thus far, Verve Therapeutics will become the third biotech to test its gene editing technology in humans. Today, the company announced that it received clearance from New Zealand regulatory authorities to begin clinical trials for its gene editing program for patients with HeFH, a common genetic disease that causes high cholesterol.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.